Kaymakcalan, Marina D <br/><br/>
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.  [electronic resource] 

 -  Cancer  Feb 2016 
 - 411-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1097-0142 
<br/><br/><label>Standard No.: </label>10.1002/cncr.29773  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--administration & dosage<br/>Axitinib<br/>Bevacizumab--administration & dosage<br/>Carcinoma, Renal Cell--blood<br/>Databases, Factual<br/>Diarrhea--chemically induced<br/>Drug Administration Schedule<br/>Fatigue--chemically induced<br/>Female<br/>Hand-Foot Syndrome--etiology<br/>Humans<br/>Imidazoles--administration & dosage<br/>Indazoles--administration & dosage<br/>Indoles--administration & dosage<br/>Kaplan-Meier Estimate<br/>Kidney Neoplasms--blood<br/>Male<br/>Middle Aged<br/>Models, Statistical<br/>Molecular Targeted Therapy--adverse effects<br/>Mucositis--chemically induced<br/>Niacinamide--administration & dosage<br/>Phenylurea Compounds--administration & dosage<br/>Predictive Value of Tests<br/>Pyrimidines--administration & dosage<br/>Pyrroles--administration & dosage<br/>Retrospective Studies<br/>Risk Assessment<br/>Risk Factors<br/>Sorafenib<br/>Sulfonamides--administration & dosage<br/>Sunitinib<br/>Vascular Endothelial Growth Factor A--drug effects